Citadel Advisors
NTGN

Citadel Advisors’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Citadel Advisors’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-116,418
Closed -$1.47M – 9951
2018
Q2 		$1.47M Buy
+116,418
New +$1.59M ﹤0.01% 4582

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Citadel Advisors's NTGN Position: Q3 2018 in Review

Citadel Advisors sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q3 2018, closing a stake of 116,418 shares — an estimated $1.47M sold.

Citadel Advisors first reported a position in NTGN in Q2 2018 and held it in 1 quarter. The position peaked at $1.47M in Q2 2018. 45 funds tracked by Wall St. Rank hold NTGN as of Q3 2018.

  • Citadel Advisors reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Citadel Advisors sold 116,418 Neon Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $1.47M.
  • Citadel Advisors first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Citadel Advisors's Neon Therapeutics, Inc. Common Stock position peaked at $1.47M in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Citadel Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.